We are live on ! Find out more
OSIR

Osiris Therapeutics, Inc. Common Stock
OSIR

Delisted

OSIR was delisted on the 16th of April, 2019.

81 hedge funds and large institutions have $100M invested in Osiris Therapeutics, Inc. Common Stock in 2015 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 30 increasing their positions, 18 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 18

12% less funds holding

Funds holding: 9281 (-11)

46% less capital invested

Capital invested by funds: $186M → $100M (-$86.3M)

50% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 20

96% less call options, than puts

Call options by funds: $162K | Put options by funds: $3.83M

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
81
Holders Change
-11
Holders Change %
-11.96%
% of All Funds
2.12%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
10
Increased
30
Reduced
18
Closed
20
Calls
$162K
Puts
$3.83M
Net Calls
-$3.66M
Net Calls Change
-$517K
Name Holding Trade Value Shares
Change
Change in
Stake
CCM
1
Consonance Capital Management
New York
$23.3M +$2.78M +205,000 +10%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$21.5M
BFA
3
BlackRock Fund Advisors
California
$9.44M -$1.14M -83,855 -8%
Vanguard Group
4
Vanguard Group
Pennsylvania
$7.25M +$309K +22,766 +3%
BIT
5
BlackRock Institutional Trust
California
$5.42M -$16.5K -1,213 -0.2%
BBA
6
Baker Bros. Advisors
New York
$5.18M
State Street
7
State Street
Massachusetts
$2.94M +$5.38K +396 +0.1%
Northern Trust
8
Northern Trust
Illinois
$2.53M -$160K -11,777 -5%
Renaissance Technologies
9
Renaissance Technologies
New York
$1.78M +$995K +73,307 +74%
QI
10
QS Investors
New York
$1.37M +$471K +34,738 +36%
Group One Trading
11
Group One Trading
Illinois
$1.32M +$1.58M +116,151 +1,045%
FIM
12
Freedom Investment Management
Connecticut
$1.23M +$1.3M +95,898 +428%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$1.16M +$86K +6,334 +6%
GCP
14
GSA Capital Partners
United Kingdom
$1.03M +$132K +9,702 +11%
Bank of New York Mellon
15
Bank of New York Mellon
New York
$910K +$70.7K +5,210 +6%
Susquehanna International Group
16
Susquehanna International Group
Pennsylvania
$837K +$503K +37,091 +85%
BIM
17
BlackRock Investment Management
Delaware
$703K +$3.98K +293 +0.4%
SIM
18
Spark Investment Management
New York
$651K +$33.9K +2,500 +4%
TCIM
19
TIAA CREF Investment Management
New York
$587K -$36.8K -2,708 -5%
Charles Schwab
20
Charles Schwab
California
$538K -$1.77M -130,602 -72%
Goldman Sachs
21
Goldman Sachs
New York
$488K -$41.6K -3,062 -6%
Deutsche Bank
22
Deutsche Bank
Germany
$472K +$472K +34,759 +317%
AA
23
ALPS Advisors
Colorado
$471K -$115K -8,443 -16%
Morgan Stanley
24
Morgan Stanley
New York
$437K +$444K +32,744 +351%
AllianceBernstein
25
AllianceBernstein
Tennessee
$393K -$19K -1,400 -4%

OSIR Hedge Fund Activity: Q4 2015 in Review

81 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Osiris Therapeutics, Inc. Common Stock (OSIR) for Q4 2015, worth a combined $100M — down 46% from $186M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of OSIR and 10 opened new positions — a net loss of 10 holders — while 18 trimmed existing stakes and 30 added.

The largest buyer was Consonance Capital Management, adding an estimated $2.78M. The largest seller was Hood River Capital Management, exiting entirely with an estimated $3.78M sold.

  • 81 institutional investors held Osiris Therapeutics, Inc. Common Stock (OSIR) as of Q4 2015, down from 92 in Q3 2015.
  • Funds reported $100M of Osiris Therapeutics, Inc. Common Stock stock for Q4 2015, down 46% quarter-over-quarter.
  • 10 funds opened new Osiris Therapeutics, Inc. Common Stock positions in Q4 2015 and 20 closed out, a net change of -10 holders.
  • The largest Osiris Therapeutics, Inc. Common Stock buyer in Q4 2015 was Consonance Capital Management, an estimated $2.78M added.
  • The largest Osiris Therapeutics, Inc. Common Stock seller in Q4 2015 was Hood River Capital Management, an estimated $3.78M sold.

Based on aggregated 13F filings for Q4 2015.